ストックスクリーナーアプリを入手
8.75
1.74%
0.15
アフターアワーズ：
8.72
-0.03
-0.34%
Arvinas Inc (ARVN) 最新ニュース
Federated Hermes Inc. Cuts Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting | ARVN Stock News - GuruFocus
Arvinas to Present Preclinical Data for PROTAC BCL6 - GlobeNewswire
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American - Bluefield Daily Telegraph
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting - TradingView
Breakthrough Cancer Treatment ARV-393 Demonstrates Powerful Results Against Lymphoma in Latest Research - Stock Titan
Affinity Asset Advisors LLC Grows Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Decreases By 28.2% - MarketBeat
Franklin Resources Inc. Has $489,000 Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Stock Position Increased by New Leaf Venture Partners L.L.C. - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by Kennedy Capital Management LLC - MarketBeat
Arvinas (NASDAQ:ARVN) shareholders are up 16% this past week, but still in the red over the last three years - simplywall.st
(ARVN) Trading Report - news.stocktradersdaily.com
Arvinas (NASDAQ:ARVN) Price Target Lowered to $21.00 at Truist Financial - MarketBeat
JPMorgan Chase & Co. Sells 472,225 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Vanguard Group Inc. Has $135.39 Million Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
HC Wainwright Reiterates Buy Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
Finepoint Capital LP Acquires 139,400 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Norges Bank Purchases New Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
American Century Companies Inc. Sells 58,788 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas (ARVN) Reports Positive Phase 3 Trial Results in Breast Cancer Treatment - GuruFocus
Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Arvinas stock target cut to $21 from $65 at Truist Securities - Investing.com Canada
Arvinas stock target cut to $21 from $65 at Truist Securities By Investing.com - Investing.com South Africa
Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple - Insider Monkey
After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN) - Yahoo Finance
Truist Slashes Price Target on Arvinas to $21 From $65, Keeps Buy Rating - marketscreener.com
10 Stocks Under $10 that Will Triple - Insider Monkey
H.C. Wainwright maintains $81 target on Arvinas stock post-data By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $81 target on Arvinas stock post-data - Investing.com
Edmond DE Rothschild Holding S.A. Acquires Shares of 80,000 Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas stock plunges to 52-week low at $6.46 amid market rout - Investing.com Canada
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study - AOL.com
Arvinas stock plunges to 52-week low at $6.46 amid market rout By Investing.com - Investing.com South Africa
Arvinas Holding Company Unveils Promising ARV-102 Trial Results - TipRanks
Arvinas : MoneyGram and Mastercard collaborate to advance digital money movement - MarketScreener
Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s - Yahoo
Arvinas Presents First-in-Human Data For ARV-102 In Neurodegenerative Diseases, Stock Down - Nasdaq
Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2 - MarketScreener
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):